公开(公告)号：US11712448B2

公开(公告)日：2023-08-01

申请号：US15106196

申请日：2014-12-19

申请人： ALGIPHARMA AS

发明人： Arne Dessen ,  Philip Rye

IPC分类号： A61K31/734 ,  A61P7/02 ,  A61K31/702 ,  A61M1/36 ,  A61L33/08 ,  A61K31/715

CPC分类号： A61K31/734 ,  A61K31/702 ,  A61K31/715 ,  A61L33/08 ,  A61M1/3673 ,  A61P7/02 ,  A61L33/08 ,  C08L5/04

摘要： The disclosure relates to an alginate oligomer of 2 to 75 monomer residues, wherein said monomer residues do not carry a sulphate group, for use as a blood anticoagulant in clinical and non-clinical applications, including in vivo, ex vivo and in vitro contexts. The invention further provides for the use of such an alginate oligomer in preparing a product or device having a reduced capacity to promote blood coagulation, wherein said alginate oligomer is provided at or on a surface of said product or device. Such products and devices form a further aspect of the invention.

公开(公告)号：US09018158B2

公开(公告)日：2015-04-28

申请号：US13376164

申请日：2010-06-03

申请人： Edvar Onsoyen ,  Rolf Myrvold ,  Arne Dessen ,  David Thomas ,  Timothy Rutland Walsh

发明人： Edvar Onsoyen ,  Rolf Myrvold ,  Arne Dessen ,  David Thomas ,  Timothy Rutland Walsh

IPC分类号： A01N37/18 ,  A61K38/04 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/734 ,  A61K45/06

CPC分类号： A61K31/734 ,  A01N37/18 ,  A01N43/22 ,  A01N43/60 ,  A01N43/72 ,  A01N43/78 ,  A01N43/86 ,  A01N43/90 ,  A61K31/407 ,  A61K31/427 ,  A61K31/496 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7028 ,  A61K31/7048 ,  A61K31/7052 ,  A61K45/06 ,  Y02A50/473 ,  A61K2300/00

摘要： The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes.

摘要翻译： 本发明提供一种在多重耐药性细菌中克服对至少一种抗生素的抗性的方法，所述方法包括使所述细菌与抗生素一起与藻酸盐低聚物接触。 多重耐药性细菌可以是生物或无生命的表面，并且提供医疗和非医疗用途和方法。 一方面，本发明提供了一种与至少一种抗生素一起使用的藻酸盐低聚物，用于治疗受多种耐药细菌感染，怀疑感染或有感染风险的受试者，以克服对所述多重耐药细菌中抗生素的抗性 。 在另一方面，该方法可用于抵抗具有多重耐药细菌的位点的污染，例如， 用于消毒和清洁目的。

公开(公告)号：US20210386666A1

公开(公告)日：2021-12-16

申请号：US17445577

申请日：2021-08-20

申请人： AlgiPharma AS

发明人： Bildad NYAMBURA ,  Anand BAKLE ,  Arne DESSEN

IPC分类号： A61K9/00 ,  A61K9/16 ,  A61P11/00 ,  A61K9/48

摘要： A method of preparing spray dried particles for inhalation comprising providing: (i) an aqueous liquid composition including the alginate oligomer and an aqueous liquid composition including an anti-adherent compound, or (ii) an aqueous liquid composition including the alginate oligomer and an anti-adherent compound; providing an organic liquid composition including a phospholipid; combining a volume of the organic liquid composition with a volume of the aqueous liquid composition, wherein the total volume of the organic liquid composition is smaller than the total volume of the aqueous liquid composition with which it is combined, and wherein the total volume of aqueous liquid composition and said total volume of organic liquid composition are sufficient to provide a combination; homogenizing the combination to form an organic-in-aqueous liquid emulsion for spray drying; and spray drying the organic-in-aqueous liquid emulsion to form the spray dried particles for inhalation.

公开(公告)号：US20210030891A1

公开(公告)日：2021-02-04

申请号：US16982240

申请日：2019-03-19

申请人： AlgiPharma AS

发明人： Aristides Tagalakis ,  Stephen Hart ,  Are Kristiansen ,  Arne Dessen ,  Philip D. Rye

IPC分类号： A61K47/69 ,  A61K47/61 ,  C12N15/113

摘要： A method for translocating a cationic micro/nanoparticle across a mucus layer, the method including (a) contacting the mucus layer with at least one alginate oligomer, the alginate oligomer having at least 70% mannuronate residues, together with the cationic micro/nanoparticle; or (b)(i) contacting the cationic micro/nanoparticle with an alginate oligomer having at least 70% mannuronate residues thereby forming a micro/nanoparticle carrying the alginate oligomer, and (b)(ii) contacting the mucus layer with the micro/nanoparticle prepared in step (b)(i). There is also provided a method for translocating a molecule of interest across a mucus layer including contacting the mucus layer with a micro/nanoparticle which is formed of self-assembling micro/nanoparticle forming components, wherein at least one is a cationic micro/nanoparticle forming agent and at least one is an alginate oligomer which has at least 70% mannuronate residues, and further comprises the molecule of interest, optionally wherein the molecule of interest is covalently bound to one or more of the self-assembling micro/nanoparticle forming components.

公开(公告)号：US20120115803A1

公开(公告)日：2012-05-10

申请号：US13376140

申请日：2010-06-03

申请人： Edvar Onsoyen ,  Rolf Myrvold ,  Arne Dessen ,  David Thomas ,  Timothy Rutland Walsh

发明人： Edvar Onsoyen ,  Rolf Myrvold ,  Arne Dessen ,  David Thomas ,  Timothy Rutland Walsh

IPC分类号： A61K31/7052 ,  A61K31/715 ,  A61P41/00 ,  A61P27/02 ,  A61P27/16 ,  A61P1/00 ,  A61P11/00 ,  A61P15/00 ,  A61P21/00 ,  A61P7/00 ,  A61P13/12 ,  A61P13/02 ,  A61P35/00 ,  A61P37/02 ,  A61P31/12 ,  A61P31/18 ,  A61P19/02 ,  A61P3/10 ,  A61P31/04

CPC分类号： A61K31/734 ,  A01N37/18 ,  A01N43/22 ,  A01N43/60 ,  A01N43/72 ,  A01N43/78 ,  A01N43/86 ,  A01N43/90 ,  A61K31/407 ,  A61K31/427 ,  A61K31/496 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7028 ,  A61K31/7048 ,  A61K31/7052 ,  A61K45/06 ,  Y02A50/473 ,  A61K2300/00

摘要： The invention provides a method to improve the efficacy of an antibiotic to inhibit the growth of Acinetobacter, said method comprising using said antibiotic together with an alginate oligomer. The Acinetobacter may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with Acinetobacter. In another aspect the method can be used to combat Acinetobacter contamination of a site e.g., for disinfection and cleaning purposes.

摘要翻译： 本发明提供了一种改善抗生素抑制不动杆菌生长的功效的方法，所述方法包括将所述抗生素与藻酸盐低聚物一起使用。 不动杆菌可能在生物或无生命的表面，并提供医疗和非医疗用途和方法。 在一个方面，本发明提供了一种与至少一种抗生素一起使用的藻酸盐低聚物，用不动杆菌治疗受感染，疑似感染或有感染风险的受试者。 在另一方面，该方法可用于抵抗位点的不动杆菌污染物，例如用于消毒和清洁目的。

公开(公告)号：US20220305050A1

公开(公告)日：2022-09-29

申请号：US17596741

申请日：2020-06-17

申请人： AlgiPharma AS

发明人： Rhodri Williams ,  Phillip Adrian Evans ,  Arne Dessen ,  Philip Rye

IPC分类号： A61K31/734 ,  A61P7/02

摘要： An alginate oligomer for use in the anticoagulation therapy of a human or non-human vertebrate subject at risk of blood clots which have an abnormally dense microstructure. In certain embodiments, the incidence of blood clots which have an abnormally dense microstructure in the subject is reduced and/or the occurrence of blood clots which have an abnormally dense microstructure in the subject is inhibited and/or the abnormal microstructure of the subject's clots is normalized. Corresponding methods of anticoagulation therapy and products of use therein are further provided.

公开(公告)号：US11413306B2

公开(公告)日：2022-08-16

申请号：US15766272

申请日：2016-10-06

申请人： AlgiPharma AS

发明人： Arne Dessen ,  Philip Rye

IPC分类号： A61K31/734 ,  A61P31/10 ,  A61K9/00 ,  A61K45/06 ,  A61K31/165 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/7036 ,  A61K31/4178 ,  A61K31/365 ,  A61K31/4245 ,  A61K31/352 ,  A61K31/192 ,  A61K36/03 ,  A61K31/522 ,  A61K31/4422 ,  A61P31/04

摘要： The invention provides a method for the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject, said method comprising administering an effective amount of an alginate oligomer to a subject in need thereof. Also provided is an alginate oligomer for use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject and a product containing an alginate oligomer and further pharmaceutical for the treatment of intestinal microbial overgrowth and/or a CFTR modulator as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject.

公开(公告)号：US10751363B2

公开(公告)日：2020-08-25

申请号：US15560984

申请日：2016-03-23

申请人： AlgiPharma AS

发明人： Arne Dessen ,  Astrid Hilde Myrset ,  Philip Rye

IPC分类号： A61K31/734 ,  A61K31/443 ,  A61K31/4245 ,  A61K31/47 ,  A61K45/06 ,  A61K31/4164 ,  A61K31/405 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/43 ,  A61K31/7036

摘要： A method is for the treatment of a condition in a subject, which arises from or is associated with CFTR dysfunction. The method includes administering to the subject an effective amount of a CFTR modulator together with an effective amount of an alginate oligomer. The condition can be cystic fibrosis (CF), non-compound CFTR gene mutation heterozygosity, abnormal mucus clearance in the respiratory tract and/or breathing difficulties resulting from chronic particulate inhalation, COPD, chronic bronchitis, emphysema, bronchiectasis, asthma or chronic sinusitis, or a complication of any of these.

公开(公告)号：US11992553B2

公开(公告)日：2024-05-28

申请号：US17445577

申请日：2021-08-20

申请人： AlgiPharma AS

发明人： Bildad Nyambura ,  Anand Bakle ,  Arne Dessen

IPC分类号： A61K9/16 ,  A61K9/00 ,  A61K9/48 ,  A61P11/00

CPC分类号： A61K9/0075 ,  A61K9/008 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1682 ,  A61K9/4808 ,  A61P11/00

摘要： A method of preparing spray dried particles for inhalation comprising providing: (i) an aqueous liquid composition including the alginate oligomer and an aqueous liquid composition including an anti-adherent compound, or (ii) an aqueous liquid composition including the alginate oligomer and an anti-adherent compound; providing an organic liquid composition including a phospholipid; combining a volume of the organic liquid composition with a volume of the aqueous liquid composition, wherein the total volume of the organic liquid composition is smaller than the total volume of the aqueous liquid composition with which it is combined, and wherein the total volume of aqueous liquid composition and said total volume of organic liquid composition are sufficient to provide a combination; homogenizing the combination to form an organic-in-aqueous liquid emulsion for spray drying; and spray drying the organic-in-aqueous liquid emulsion to form the spray dried particles for inhalation.

公开(公告)号：US11385174B2

公开(公告)日：2022-07-12

申请号：US17264559

申请日：2019-07-30

申请人： AlgiPharma AS

发明人： Arne Dessen ,  Philip Rye ,  Paul Lewis

IPC分类号： G01N21/35 ,  G01N21/3577 ,  G01N33/487

摘要： Qualitative and quantitative methods are for the detection of alginate oligomers in body fluids based on analyzing the Fourier transform infrared spectroscopy (FTIR) spectrum of a body fluid sample, for example a sputum sample, at a specific wave number range and, more particularly, certain specific characteristic wavenumbers.